Eos Energy stock falls after Fuzzy Panda issues short report
Investing.com - Evercore ISI has reiterated an Outperform rating on West Pharmaceutical (NYSE:WST), a $21.4 billion pharmaceutical packaging company, with a price target of $390.00. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock, which currently trades at $297.47 and appears overvalued based on Fair Value estimates.
The research firm maintained its positive outlook on the pharmaceutical packaging and delivery systems company following West Pharmaceutical’s earnings report released late last week.
Evercore ISI had previously included West Pharmaceutical on its TAP (tactical, actionable, positioning) Outperform list ahead of the earnings announcement.
With the earnings report now complete, the firm has removed West Pharmaceutical from its TAP list while maintaining the overall Outperform rating and $390.00 price target.
TransMedics Group (TMDX) remains on Evercore ISI’s TAP list, with that company scheduled to report earnings in the coming week.
In other recent news, West Pharmaceutical Services Inc. reported its third-quarter earnings for 2025, surpassing market expectations with an adjusted earnings per share (EPS) of $1.96, compared to the forecasted $1.69. The company also reported revenue of $805 million, exceeding the anticipated $786.33 million, and subsequently raised its full-year revenue guidance to between $3.06 billion and $3.07 billion. These positive earnings results have been complemented by several analyst actions. KeyBanc increased its price target for West Pharmaceutical to $350 from $325, citing approximately 9% organic growth in the third quarter. BofA Securities raised its price target to $370 from $310, expressing confidence in the company’s growth outlook with management supporting approximately 6% topline growth projections for 2026. Evercore ISI also increased its price target to $390 from $350, noting that its "bull thesis is coming to life" with the High-Value Product Components strategy unfolding as expected. These developments indicate a positive sentiment among analysts regarding West Pharmaceutical’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.